ANKRD24

Across TCGA pan-cancer cohorts, ANKRD24 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANKRD24 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ANKRD24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD24 expression acts as an unfavorable survival marker.

STAD, LUAD, and PAAD are the cancer types where ANKRD24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
PAAD	DFS	Median	All	0.006	0.505	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	OS	Median	All	0.752	0.924	.035	6	view →
LIHC	DFS	Median	All	0.094	0.530	.002	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANKRD24–STAD (OS)

Open the STAD breakdown →